First-line Inavolisib/placebo Plus Palbociclib Plus Fulvestrant (inavo/pbo Plus Palbo Plus Fulv) in Patients (pts) with PIK3CA-mutated, Hormone Receptor-Positive, HER2-negative Locally Advanced/metastatic Breast Cancer Who Relapsed During/within 12 Months (mo) of Adjuvant Endocrine Therapy Completion: INAVO120 Phase III Randomized Trial Additional Analyses